Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Blocking a Cell Cycle Inhibitor Stimulates Replication of Insulin-Producing Beta Cells

By BiotechDaily International staff writers
Posted on 27 Jan 2014
Image: Replicating human beta cells. In cells where p57 was successfully inhibited, beta cells could undergo DNA replication. Pink: nucleus that has undergone DNA replication. Green: Insulin. Blue: Nuclei counterstained for DNA. White: p57 (Photo courtesy of Dr. Klaus Kaestner, University of Pennsylvania).
Image: Replicating human beta cells. In cells where p57 was successfully inhibited, beta cells could undergo DNA replication. Pink: nucleus that has undergone DNA replication. Green: Insulin. Blue: Nuclei counterstained for DNA. White: p57 (Photo courtesy of Dr. Klaus Kaestner, University of Pennsylvania).
Diabetes researchers have found that they could stimulate replication of mature pancreatic beta cells by blocking the activity of the cell cycle inhibitor protein p57Kip2.

The CDKN1C gene encodes the protein p57Kip2, which is a potent tight-binding inhibitor of several G1 cyclin/CDK complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to lesser extent, of the mitotic cyclin B-CDC2. It is a negative regulator of cell proliferation and may play a role in the maintenance of the nonproliferative state throughout life. It is expressed in the heart, brain, lung, skeletal muscle, kidney, pancreas, and testis.

Investigators at the University of Pennsylvania (Philadelphia, USA) and their colleagues at the Hebrew University of Jerusalem (Israel) used short hairpin RNA (shRNA) to suppress the CDKN1C gene in human beta cells obtained from deceased adult donors.

They reported in the January 16, 2014, online edition of the Journal of Clinical Investigation that when human pancreatic tissue with inhibited p57Kip2 activity was transplanted into hyperglycemic, immunodeficient mice, beta cell replication increased more than three-fold. The newly replicated cells retained properties of mature beta cells, including the expression of beta cell markers such as insulin, PDX1, and NKX6.1. Furthermore, these newly replicated cells demonstrated normal glucose-induced calcium influx, further indicating beta cell functionality.

These results showed that beta cells from older humans, in which baseline replication is negligible, could be coaxed to reenter and complete the cell cycle while maintaining mature beta cell properties. Controlled manipulation of this pathway holds promise for the expansion of beta cells in patients with type II diabetes.

Related Links:

University of Pennsylvania
Hebrew University of Jerusalem



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.